AI English summary of an SEC filing — figures as filed
Becton Dickinson BDXBD said it issued June 7, 2024 €1,000,000,000 aggregate principal amount of 3.828% Notes due 2032 (BD Euro Notes). The company said it plans to use the net proceeds to fund the cash consideration for the acquisition of Edwards Lifesciences' Critical Care business, among other uses.
Key points
AI summaryBD said it issued June 7, 2024 €1,000,000,000 aggregate principal amount of 3.828% Notes due 2032 (BD Euro Notes). The company said it plans to use the net proceeds to fund the cash consideration for the acquisition of Edwards Lifesciences' Critical Care business, among other uses.
The company said Becton Dickinson Euro Finance S.à r.l., an indirect wholly owned subsidiary in which it holds 100%, issued €800,000,000 aggregate principal amount of 4.029% Notes due 2036 on June 7, 2024. It said BD fully and unconditionally guarantees the notes on a senior unsecured basis.
BD said it issued $600,000,000 aggregate principal amount of 5.081% Notes due 2029 on June 7, 2024. If the acquisition is not completed by June 3, 2025 or other set deadlines, the notes are subject to a Special Mandatory Redemption at a price equal to 101% of principal plus unpaid interest, and the offering proceeds will not be placed in an escrow account.
The company said it plans to use the net proceeds from the three note offerings, together with commercial paper borrowings and cash on hand, for the cash consideration for the acquisition of Edwards Lifesciences' Critical Care business, related fees and expenses, and general corporate purposes. It said each offering is not conditioned on completion of the acquisition, and it explained that there is no assurance the acquisition will be completed.
Summary
AI-writtenAnalysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
BD issues €1,000,000,000 3.828% Notes due 2032
BD said it issued June 7, 2024 €1,000,000,000 aggregate principal amount of 3.828% Notes due 2032 (BD Euro Notes). The company said it plans to use the net proceeds to fund the cash consideration for the acquisition of Edwards Lifesciences' Critical Care business, among other uses.
Source · Based on the filing body and exhibits
Becton Finance issues €800,000,000 4.029% Notes due 2036
The company said Becton Dickinson Euro Finance S.à r.l., an indirect wholly owned subsidiary in which it holds 100%, issued €800,000,000 aggregate principal amount of 4.029% Notes due 2036 on June 7, 2024. It said BD fully and unconditionally guarantees the notes on a senior unsecured basis.
Source · Based on the filing body and exhibits
$600,000,000 5.081% Notes due 2029 and Special Mandatory Redemption terms
BD said it issued $600,000,000 aggregate principal amount of 5.081% Notes due 2029 on June 7, 2024. If the acquisition is not completed by June 3, 2025 or other set deadlines, the notes are subject to a Special Mandatory Redemption at a price equal to 101% of principal plus unpaid interest, and the offering proceeds will not be placed in an escrow account.
Source · Based on the filing body and exhibits
Three note offerings to fund Edwards Lifesciences Critical Care acquisition
The company said it plans to use the net proceeds from the three note offerings, together with commercial paper borrowings and cash on hand, for the cash consideration for the acquisition of Edwards Lifesciences' Critical Care business, related fees and expenses, and general corporate purposes. It said each offering is not conditioned on completion of the acquisition, and it explained that there is no assurance the acquisition will be completed.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…